单用他克莫司和联合五酯胶囊治疗免疫性肾小球疾病的单中心回顾性研究

发布时间：2018-05-07 16:50

本文选题：免疫性肾小球疾病 + 他克莫司　；参考：《医学与哲学(B)》2017年05期

【摘要】：对单用他克莫司和联合五酯胶囊治疗免疫性肾小球疾病疗效、安全性和药物-经济效益进行比较。回顾性分析大连医科大学附属第一医院2011年1月~2015年12月行肾活检证实为免疫性肾小球疾病并伴大量蛋白尿的患者60例,分为单用他克莫司组和联合五酯胶囊组。主要评价指标:蛋白尿缓解率、各个时间点蛋白尿缓解率等;次要评价指标:药物副作用、治疗费用及药物-经济学效益。随访第3个月、6个月,他克莫司联合五酯胶囊组蛋白尿缓解人数高于单用他克莫司组(P0.05),两组副作用无差异(P0.05),而治疗费用及成本-疗效比有统计学差异(P0.05);他克莫司联合五酯胶囊可有效降低免疫性肾小球疾病蛋白尿,且具有较好药物经济学效益。
[Abstract]:The efficacy, safety and pharmaco-economic benefit of tacrolimus and pentyl ester capsules in the treatment of immune glomerular diseases were compared. From January 2011 to December 2015, 60 patients with immunologic glomerular disease and large proteinuria were analyzed retrospectively. They were divided into two groups: tacrolimus group and combined pentyl ester capsule group. Main outcome measures: remission rate of proteinuria, remission rate of proteinuria at different time points, secondary evaluation measures: side effects of drugs, treatment costs and pharmaco-economic benefits. They were followed up for 3 months, 6 months, The remission of proteinuria in tacrolimus combined with pentyl ester capsule group was higher than that in tacrolimus group alone, and there was no difference in side effects between the two groups (P 0.05), while there was significant difference in the cost of treatment and the ratio of cost to curative effect (P 0.05), and tacrolimus combined with pentyl ester capsule was effective in reducing the incidence of proteinuria. Low immune glomerular disease proteinuria, And has good pharmacoeconomics benefit.
【作者单位】：大连医科大学附属第一医院肾内科;
【分类号】：R692.6

【相似文献】